Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Late phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Yamada K, Ohno R, Oguri T, Kamiya O, Yokomaku S, Kobayashi M, Nishiwaki H, Tanaka M, Inagaki J, Mitomo Y, et al. Yamada K, et al. Among authors: kamiya o. Gan To Kagaku Ryoho. 1991 Nov;18(14):2447-52. Gan To Kagaku Ryoho. 1991. PMID: 1952964 Japanese.
[Phase II study of carboplatin in malignant lymphoma].
Naito K, Kobayashi M, Oyama A, Kodera Y, Tanaka M, Kamiya O, Mitomo Y, Ohno R, Sampi K, Hirano M, et al. Naito K, et al. Among authors: kamiya o. Gan To Kagaku Ryoho. 1988 Jul;15(7):2145-51. Gan To Kagaku Ryoho. 1988. PMID: 3293537 Japanese.
A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Nagura E, Ichikawa A, Kamiya O, Kato R, Utsumi M, Tanaka M, Takeyama H, Shimizu K, Kobayashi M, Naito K, Nishiwaki H, Mizuno H, Hirabayashi N, Nitta M, Kato Y, Shibata T, Hotta T, Kawashima K, Saito H. Nagura E, et al. Among authors: kamiya o. Cancer Chemother Pharmacol. 1997;39(4):279-85. doi: 10.1007/s002800050573. Cancer Chemother Pharmacol. 1997. PMID: 9025767 Clinical Trial.
[Phase II study with methyl-6[[[2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU) in hematological malignancies].
Masaoka T, Kimura K, Miyazaki T, Sakurada K, Saitoh H, Morioka M, Fujimoto N, Musashi M, Wakui A, Yokoyama M, Kanamaru R, Oguro M, Takagi T, Konda C, Saitoh T, Nakao I, Harashima S, Ohhashi Y, Sakai Y, Sasaki T, Ohno R, Katoh Y, Yamada K, Hirota Y, Takada T, Hoshino A, Ohara K, Kamiya O, Kojima T, Nagata K, Nakamura T, Sasada M, Yonezawa T, Tsubakio T, Kanayama Y, Kitani T, Taniguchi N, Yasunaga K, Okamoto Y, Fujitake H, Ohkubo A, Horiuchi A, Tsubaki K, Takubo T, Shibata H, Kawagoe H, Hirata M, Matsubuchi T, Nagai K, Fujita S. Masaoka T, et al. Among authors: kamiya o. Gan To Kagaku Ryoho. 1983 Jun;10(6):1518-23. Gan To Kagaku Ryoho. 1983. PMID: 6347081 Clinical Trial. Japanese.
Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
Shimizu K, Kamiya O, Hirabayashi N, Ichikawa A, Kawashima K, Kobayashi M, Mizuno H, Nagura E, Nitta M, Saito H, Sao H, Shibata T, Takeyama H. Shimizu K, et al. Among authors: kamiya o. Jpn J Cancer Res. 1999 Mar;90(3):355-60. doi: 10.1111/j.1349-7006.1999.tb00755.x. Jpn J Cancer Res. 1999. PMID: 10359052 Free PMC article.
34 results